Dr. Tan has longstanding research interests in methods for the design, monitoring and analysis of clinical trials and predictive analytics in clinical trials and Big data. One of his current research foci is statistical methods for searching and evaluating multi-drug combinations utilizing both experimental data and system biology, innovative methods to optimally design and efficiently analyze pre-clinical drug combination therapies in cancer by integrating concepts in modern statistical and number-theoretic methods and pharmacology; and high dimensional genomics data analysis in Cancer Epidemiology, all funded by R01 grants from the NCI and NHLBI. Dr. Tan also has extensive collaborative research experience in the design, conduct and analysis of clinical trials (in both multi-center and single institutional settings), laboratory investigations, biomarker evaluation, genomics and epidemiological research. Dr. Tan has served on multiple NIH panels and scientific review boards, Data and Safety Monitoring Boards, and FDA Advisory Committees. He is an elected Fellow of the American Statistical Association and an elected Member of the International Statistical Institute. Dr. Tan is Executive Editor of Molecular Carcinogenesis; and Associate Editor of Statistics in Medicine and Drug Design, Development and Therapy, and has served on the editorial board for Biometrics. Before joined Georgetown in the fall of 2012, he was professor of Epidemiology and Public Health and Head of the Division of Biostatistics and Bioinformatics of the University of Maryland School of medicine and Marlene and Stewart Greenebaum Cancer Center (UMGCC) (2002-2012). He was previously a senior member (faculty) at St. Jude Children's Research Hospital Cancer Center and biostatistics director of St Jude's Developmental Therapeutics for Solid Malignancies Program (1997-2002), assistant and associate staff/professor of Biostatistics and Epidemiology at the Cleveland Clinic (1990-1997).
